Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology
Date
2024-01
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Cambridge University Press
Series Info
Expert Reviews in Molecular Medicine;Volume 268 January 2024 Article number e1
Scientific Journal Rankings
Abstract
The host immune system status remains an unresolved mystery among several malignancies.
An immune-compromised state or smart immune-surveillance tactics orchestrated by cancer
cells are the primary cause of cancer invasion and metastasis. Taking a closer look at the
tumour-immune microenvironment, a complex network and crosstalk between infiltrating
immune cells and cancer cells mediated by cytokines, chemokines, exosomal mediators and
shed ligands are present. Cytokines such as interleukins can influence all components of
the tumour microenvironment (TME), consequently promoting or suppressing tumour
invasion based on their secreting source. Interleukin-10 (IL-10) is an interlocked cytokine
that has been associated with several types of malignancies and proved to have paradoxical
effects. IL-10 has multiple functions on cellular and non-cellular components within the
TME. In this review, the authors shed the light on the regulatory role of IL-10 in the TME
of several malignant contexts. Moreover, detailed epigenomic and pharmacogenomic
approaches for the regulation of IL-10 were presented and discussed.
Description
Keywords
Cancer; Cytokines; IL-10; Interleukins; Non-coding RNAs; Pharmacogenomics; Tumour-microenvironment